Denator
Denator: Stabilizing the Proteome for Clinical Research.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
€50.0k | Grant | ||
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (47 %) | 17 % | (29 %) | 98 % | (95 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (239 %) | (30 %) | (93 %) | 4 % | (1379 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (251 %) | (38 %) | (109 %) | (5 %) | (1577 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Denator is a pioneering company in the field of biological sample preservation, focusing on stabilizing biological tissues and fluids at the moment of sampling. The company employs a unique heat inactivation technology that ensures the immediate and permanent preservation of proteins, peptides, and other small molecules. This technology prevents any biological changes that typically occur after sampling, providing more accurate and reliable results compared to traditional methods like snap freezing or using chemical inhibitors.
Denator's primary clients are researchers and scientists involved in protein, peptide, and biomarker research. These professionals require their analytical results to closely reflect the in vivo state—the natural condition within a living organism. By using Denator's heat stabilization technology, researchers can achieve homogenous and irreversible denaturation of proteins, which means that all enzymatic activities are permanently halted, ensuring sample integrity.
Operating in the clinical research market, Denator serves a niche but critical segment where the accuracy of biological sample analysis is paramount. The company’s business model revolves around selling its proprietary heat stabilization equipment and related consumables to research institutions, pharmaceutical companies, and academic laboratories. Revenue is generated through the direct sale of these products, as well as through ongoing support and maintenance services.
Denator's technology is particularly valuable for mass spectrometry analyses, where the quality of the sample can significantly impact the results. By providing a method that stabilizes samples without the need for additives or inhibitors, Denator enables researchers to obtain more precise and reliable data, which can accelerate the pace of scientific discovery and innovation.
Keywords: biological sample preservation, heat inactivation, protein stabilization, peptide research, biomarker analysis, clinical research, mass spectrometry, enzymatic activity, research institutions, pharmaceutical companies.